Eisai and Biogen
E132619
Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Eisai and Biogen canonical | 4 |
How this entity was disambiguated
This entity first appeared as the object of triple T1103703 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Eisai and Biogen Context triple: [Leqembi, coDevelopedBy, Eisai and Biogen]
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
C.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
-
D.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
E.
Merck & Co.
Merck & Co. is a major American pharmaceutical company known for developing and producing vaccines, oncology drugs, and other innovative medicines.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Eisai and Biogen Target entity description: Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
-
A.
Biogen
Biogen is a major American biotechnology company known for developing therapies for neurological and neurodegenerative diseases.
-
B.
Eisai
Eisai is a Japanese pharmaceutical company known for developing treatments in neurology and oncology, including Alzheimer’s disease therapies.
-
C.
Eli Lilly and Company
Eli Lilly and Company is a major American pharmaceutical corporation known for developing and manufacturing a wide range of prescription medicines, including treatments for diabetes, cancer, and mental health disorders.
-
D.
Genentech
Genentech is a pioneering American biotechnology company known for developing groundbreaking therapies and being one of the first firms to apply genetic engineering to medicine.
-
E.
Merck & Co.
Merck & Co. is a major American pharmaceutical company known for developing and producing vaccines, oncology drugs, and other innovative medicines.
- F. None of above. chosen
Statements (44)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
monoclonal antibody ⓘ monoclonal antibody ⓘ pharmaceutical company ⓘ pharmaceutical company ⓘ strategic partnership ⓘ |
| collaborateOn |
development of anti-amyloid beta antibodies
ⓘ
development of therapies for Alzheimer’s disease ⓘ development of therapies for neurodegenerative diseases ⓘ |
| collaboratesWith |
Biogen
ⓘ
Eisai ⓘ |
| conduct | clinical trials in Alzheimer’s disease ⓘ |
| country |
Japan
ⓘ
United States of America ⓘ
surface form:
United States
|
| developed |
Aduhelm
ⓘ
surface form:
aducanumab
Leqembi ⓘ
surface form:
lecanemab
|
| developedBy |
Eisai and Biogen
self-linksurface differs
ⓘ
Eisai and Biogen self-linksurface differs ⓘ |
| fieldOfWork |
neurodegeneration
ⓘ
neurology ⓘ neuroscience ⓘ |
| focusesOn |
Alzheimer's disease
ⓘ
surface form:
Alzheimer’s disease
Alzheimer's disease ⓘ
surface form:
Alzheimer’s disease
neurodegenerative diseases ⓘ neurodegenerative diseases ⓘ |
| focusOn |
disease-modifying treatments for neurodegenerative disorders
ⓘ
innovative therapies for dementia ⓘ |
| goal | develop disease-modifying therapies for Alzheimer’s disease ⓘ |
| headquartersLocation |
Cambridge, Massachusetts
ⓘ
surface form:
Cambridge, Massachusetts, United States
Tokyo ⓘ
surface form:
Tokyo, Japan
|
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ pharmaceuticals ⓘ |
| researchFocus |
amyloid beta–directed therapies
ⓘ
disease-modifying Alzheimer’s treatments ⓘ |
| targets |
amyloid beta
ⓘ
amyloid beta protofibrils ⓘ |
| therapeuticArea |
Alzheimer's disease
ⓘ
surface form:
Alzheimer’s disease
dementia ⓘ neurodegenerative diseases ⓘ |
| treats |
Alzheimer's disease
ⓘ
surface form:
Alzheimer’s disease
Alzheimer’s disease ⓘ |
| typeOfCollaboration |
co-commercialization agreement
ⓘ
co-development agreement ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Eisai and Biogen Description of subject: Eisai and Biogen are pharmaceutical companies that collaborate on developing innovative therapies, particularly in the field of neurodegenerative diseases such as Alzheimer’s.
Referenced by (4)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
aducanumab
subject surface form:
lecanemab